William Blair & Company
ABUS icon

William Blair & Company’s Arbutus Biopharma ABUS Stock Holding History

William Blair & Company’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,700
Closed -$45K – 1725
2019
Q1 		$45K Buy
12,700
+500
+4% +$1.92K ﹤0.01% 1482
2018
Q4 		$47K Buy
12,200
+2,100
+21% +$10.3K ﹤0.01% 1396
2018
Q3 		$95K Buy
10,100
+100
+1% +$993 ﹤0.01% 1383
2018
Q2 		$73K Buy
+10,000
New +$59.5K ﹤0.01% 1375

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

William Blair & Company's ABUS Position: Q2 2019 in Review

William Blair & Company sold out of Arbutus Biopharma (ABUS) in Q2 2019, closing a stake of 12,700 shares — an estimated $45K sold.

William Blair & Company first reported a position in ABUS in Q2 2018 and held it in 4 quarters. The position peaked at $95K in Q3 2018. 62 funds tracked by Wall St. Rank hold ABUS as of Q2 2019.

  • William Blair & Company reported no remaining Arbutus Biopharma position as of Q2 2019 after selling out during the quarter.
  • William Blair & Company sold 12,700 Arbutus Biopharma shares in Q2 2019, an estimated $45K.
  • William Blair & Company first reported a position in Arbutus Biopharma in Q2 2018 and held it in 4 quarters.
  • William Blair & Company's Arbutus Biopharma position peaked at $95K in Q3 2018.
  • 62 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2019.

Based on William Blair & Company's 13F filing for Q2 2019, filed 13 Aug 2019.